Abstract
Background: The high mortality rate of tobacco consumption shows the importance of smoking cessation. Several biomarkers studies have been conducted to evaluate smoking cessation efforts. Exhaled carbon monoxide (eCO) and cotinine can provide an objective picture of a person’s smoking status. Smoking cessation centre had limited data for cotinine levels serum and urine.
Method: Cross sectional analytical study design on 34 subjects who met the inclusions and exclusions criteria that examined and analysed the characteristics of smokers, eCO, cotinine serum and cotinine urine levels. The eCO levels are divided into mild, moderate and severe stages.
Results: 17 subjects with mild eCO had an average 13,941 ± 2,357 ppm with cotinine serum 5,221 ± 3,309 ng/mL and cotinine urine 10,971 ± 4,547 ng/mL. 15 subjects with moderate eCO had an average 26,6 ± 5,234 ppm with cotinine serum 12,332 ± 12,226 ng/mL and cotinine urine 6,587 ± 3,594 ng/mL. 2 subjects with severe eCO had an average 43,5 ± 3,533 ppm with cotinine serum 98,101 ± 6,074 ng/mL and cotinine urine 7,022 ± 1,37 ng/mL.
Conclusion: The increased of cotinine serum was consistent with the eCO stages. Cotinine serum can be predicted from eCO stage.
Keywords: Smoking cessation, eCO, cotinine serum, cotinine urine
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA2441.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
